NCT00353522View on ClinicalTrials.gov

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

PHASE2CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Coronary Heart Disease

Interventions

DRUG

Placebo

po daily for 24 weeks

DRUG

dalcetrapib

900mg po daily for 24 weeks

Trial Locations (17)

10707

Berlin

20249

Hamburg

20817

Bethesda

28677

Statesville

40213

Louisville

44137

Dortmund

45212

Cincinnati

45219

Cincinnati

46260

Indianapolis

52242

Iowa City

55455

Minneapolis

60610

Chicago

79106

Freiburg im Breisgau

80336

München

84132

Salt Lake City

91054

Erlangen

06097

Bochum

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00353522 - A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent. | Biotech Hunter | Biotech Hunter